Clinical Trial Update: Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials [Phase 3]

View source ↗

Summary

Aripiprazole for schizophrenia outpatients has completed Phase 3 trials, with results posted in 2014 as part of a Bristol-Myers Squibb and Otsuka collaboration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Abilify (aripiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2014-01-10